NCT05901584 is a Phase 2 clinical trial of Cadonilimab in Immunotherapy, sponsored by Second Affiliated Hospital of Zunyi Medical University.

Who is sponsoring NCT05901584?

NCT05901584 is sponsored by Second Affiliated Hospital of Zunyi Medical University.

What drugs are being tested in NCT05901584?

Interventions in NCT05901584: Cadonilimab.

What condition does NCT05901584 study?

NCT05901584 studies Immunotherapy, Second-line Treatment.

Is NCT05901584 still recruiting?

NCT05901584 is currently status unknown. Last updated 14 June 2023.

Last reviewed 2023-06-14 · How we verify

NCT05901584

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single-arm Multicenter Phase II Clinical Trial of Cadunilumab (Anti-PD-1/CTLA-4) in Combination With or Without Chemotherapy in Second-line Treatment for Patients With Extensive Stage Small Cell Lung Cancer

Status unknown Phase 2 Last updated 14 June 2023

What this trial tests

Phase 2 trial testing Cadonilimab in Immunotherapy in 30 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
1 December 2024

1 December 2024

Quick facts

Lead sponsor	Second Affiliated Hospital of Zunyi Medical University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	30
Start date	1 January 2023
Primary completion	1 December 2024
Estimated completion	1 December 2024
Sites	1 location across China

Drugs / interventions tested

Cadonilimab — full drug profile →

Conditions studied

Immunotherapy — all drugs for Immunotherapy →
Second-line Treatment — all drugs for Second-line Treatment →

Sponsor

Second Affiliated Hospital of Zunyi Medical University

Who can join

Adults 18 to 75, any sex, with Immunotherapy or Second-line Treatment. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Progression-free survival，PFS
Time frame: Time Frame: The last subject completes at least 24 weeks of follow-up (or disease progression)
The time from the beginning of the patient's treatment to the disease progression or death for any reason.Based on RECIST v i I Assessed PFS

Sponsor's own description

This study is a phase II clinical study of Cadonilimab (AK104) combined with or without chemotherapy in the treatment of PD-1 inhibitor-resistant extensive stage small cell lung cancer

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer.
Cheng W, Kang K, Zhao A, Wu Y. · · 2024 · cited 110× · PMID 39068460 · DOI 10.1186/s13045-024-01581-2
A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer.
Chen C, Chen M, Bai Y, Li Y, et al · · 2024 · cited 8× · PMID 38706247 · DOI 10.1177/15330338241249690
The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics.
Trillo Aliaga P, Del Signore E, Fuorivia V, Spitaleri G, et al · · 2024 · cited 5× · PMID 38927637 · DOI 10.3390/genes15060701
Next-generation immunotherapy: igniting new hope for lung cancer.
Li MSC, Chan ALS, Mok KKS, Chan LL, et al · · 2024 · cited 3× · PMID 39649017 · DOI 10.1177/17588359241302021
The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances.
Chen H, Yang H, Guo L, Sun Q. · · 2025 · cited 1× · PMID 41059489 · DOI 10.1002/mco2.70412
Expanding the immunotherapy universe in extensive-stage small cell lung cancer: from chemoimmunotherapy backbone to next-wave combinations.
Chi X, Dong Y, Zhu L, Su D, et al · · 2025 · PMID 41415276 · DOI 10.3389/fimmu.2025.1693401

Verify or expand the search:

Other trials of Cadonilimab

Trials testing the same drug.

NCT07446257 — THIO and Cadonilimab in Resectable Hepatocellular Carcinoma · EARLY_PHASE1 · not yet recruiting
NCT07243951 — Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therap · Phase 2 · not yet recruiting
NCT06913218 — A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically R · Phase 1 · not yet recruiting
NCT06940921 — SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases · Phase 1, PHASE2 · active not recruiting
NCT06789848 — Ligufalimab and Cadonilimab in Advanced Liver Cancers · Phase 2 · recruiting

Other recruiting trials for Immunotherapy

Currently open trials in the same condition.

NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07458529 — Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer · Phase 2 · recruiting
NCT07436845 — Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arte · recruiting
NCT06671613 — Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer · NA · recruiting

Other Second Affiliated Hospital of Zunyi Medical University trials

Trials by the same sponsor.

NCT06725225 — Machine Learning for Predicting and Managing Quality of Life in Lung Cancer Immunotherapy Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05901584 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Zunyi Medical University
Last refreshed: 14 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05901584.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing